Endometrial Safety of a Low Dose Continuous Combined 17 -Estradiol/Dydrogesterone Hormone Replacement Regimen (E2 0.5 mg/ D 2.5 mg) in Postmenopausal Women - A One-Year, Open Label, Multi-Center Study
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Presence of endometrial hyperplasia or a more serious endometrial outcome during the 52 week treatment period
52 weeks
Yes
Global Clinical Director Solvay
Study Director
Solvay Pharmaceuticals
Romania: State Institute for Drug Control
S102.3.117
NCT00160316
April 2005
December 2007
Name | Location |
---|